The New Direct Antiviral Agents and Hepatitis C in Thoracic Transplantation: Impact on Donors and Recipients
Purpose of Review The landscape of abdominal organ transplantation has been altered by the emergence of curative direct-acting antiviral agents for hepatitis C. Expansion of the thoracic donor pool to include the hearts and the lungs from hepatitis C-positive donors holds promise to increase available donor organs. Recent Findings Case reports have documented separate lung and heart transplant patients who acquired, and then were cured of, donor-derived hepatitis C using these newer, more effective therapies. Single sites and national consortia are underway to help make this approach part of the standard-of-care. Pangenotypic therapies may simplify the paradigm. Summary Organs from donors with active hepatitis C viremia are likely suitable for transplant as long as the organ is otherwise acceptable. Best-practices for “informed-risk” transplant include a team-based approach and a selection of the antiviral regimen based on insurer’s formulary, potential drug interactions, and genotype..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
Current transplantation reports - 5(2018), 2 vom: 10. Apr., Seite 145-152 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gottlieb, Robert L. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Direct-acting antiviral |
|---|
| Anmerkungen: |
© The Author(s) 2018 |
|---|
| doi: |
10.1007/s40472-018-0192-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR036495328 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR036495328 | ||
| 003 | DE-627 | ||
| 005 | 20230519193139.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40472-018-0192-y |2 doi | |
| 035 | |a (DE-627)SPR036495328 | ||
| 035 | |a (SPR)s40472-018-0192-y-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gottlieb, Robert L. |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The New Direct Antiviral Agents and Hepatitis C in Thoracic Transplantation: Impact on Donors and Recipients |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2018 | ||
| 520 | |a Purpose of Review The landscape of abdominal organ transplantation has been altered by the emergence of curative direct-acting antiviral agents for hepatitis C. Expansion of the thoracic donor pool to include the hearts and the lungs from hepatitis C-positive donors holds promise to increase available donor organs. Recent Findings Case reports have documented separate lung and heart transplant patients who acquired, and then were cured of, donor-derived hepatitis C using these newer, more effective therapies. Single sites and national consortia are underway to help make this approach part of the standard-of-care. Pangenotypic therapies may simplify the paradigm. Summary Organs from donors with active hepatitis C viremia are likely suitable for transplant as long as the organ is otherwise acceptable. Best-practices for “informed-risk” transplant include a team-based approach and a selection of the antiviral regimen based on insurer’s formulary, potential drug interactions, and genotype. | ||
| 650 | 4 | |a Hepatitis C |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Heart transplant |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Lung transplant |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Direct-acting antiviral |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Organ allocation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Donor shortage |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Hall, Shelley A. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current transplantation reports |d Cham : Springer Internat. Publ., 2014 |g 5(2018), 2 vom: 10. Apr., Seite 145-152 |w (DE-627)SPR036493228 |w (DE-600)2760306-4 |x 2196-3029 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2018 |g number:2 |g day:10 |g month:04 |g pages:145-152 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40472-018-0192-y |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2018 |e 2 |b 10 |c 04 |h 145-152 | ||